Literature DB >> 25926412

The Antiatherogenic Effect of Fish Oil in Male Mice Is Associated with a Diminished Release of Endothelial ADAM17 and ADAM10 Substrates.

Nancy Speck1, Corinna Brandsch2, Nadine Schmidt2, Narges Yazdekhasti2, Frank Hirche2, Ralph Lucius3, Gerald Rimbach4, Gabriele I Stangl2, Karina Reiss5.   

Abstract

BACKGROUND: Growing evidence suggests that disintegrin and metalloprotease (ADAM) 17 (ADAM17) and ADAM10 contribute to the pathogenesis of vascular diseases. ADAM17 promotes inflammatory processes by liberating tumor necrosis factor α, interleukin 6 receptor (IL-6R), and tumor necrosis factor receptor 1 (TNFR1). ADAM17 and ADAM10 modulate vascular permeability by cleaving endothelial adhesion molecules such as junctional adhesion molecule A (JAM-A) and vascular endothelial cadherin (VE-cadherin), respectively.
OBJECTIVE: This study was designed to investigate whether a link might exist between the protective effects of fish oil (FO) supplementation against atherosclerosis and ADAM function.
METHODS: Male LDL receptor knockout (LDLR(-/-)) mice and male wild-type (WT) mice were fed a Western diet (200 g/kg fat, 1.5 g/kg cholesterol) containing either 20% lard (LDLR(-/-)-lard and WT-lard groups) or 10% lard combined with 10% FO (LDLR(-/-)-FO and WT-FO groups) for 12 wk. Atherosclerotic lesion development and fatty acid composition of liver microsomes were evaluated. ADAM10 and ADAM17 expression was determined by quantitative real-time polymerase chain reaction and immunoblot analyses. Concentrations of soluble ADAM substrates in plasma and liver extracts were measured by ELISA.
RESULTS: Diets supplemented with FO markedly reduced development of early atherosclerotic lesions in LDLR(-/-) mice (LDLR(-/-)-lard group vs. LDLR(-/-)-FO group mean ± SD: 29.6 ± 6.1% vs. 22.5 ± 4.2%, P < 0.05). This was not accompanied by changes in expression of ADAM17 or ADAM10 in the aorta or liver. No dietary effects on circulating TNFR1 (LDLR(-/-)-lard group vs. LDLR(-/-)-FO group mean ± SD: 1.22 ± 0.23 vs. 1.39 ± 0.28, P > 0.2) or IL-6R (1.06 ± 0.12 vs. 0.98 ± 0.09 fold of WT-lard group, P > 0.1), classical substrates of ADAM17 on macrophages, and neutrophil granulocytes were observed. However, a reduction in atherosclerotic lesions in the LDLR(-/-)-FO group was accompanied by a significant reduction in the circulating endothelial cell adhesion molecules JAM-A (LDLR(-/-)-lard group vs. LDLR(-/-)-FO group mean ± SD: 1.42 ± 0.20 vs. 0.95 ± 0.56 fold of WT-lard group, P < 0.05), intercellular adhesion molecule 1 (1.15 ± 0.14 vs. 0.88 ± 0.17 fold of WT-lard group, P < 0.05), and VE-cadherin (0.88 ± 0.12 vs. 0.72 ± 0.15 fold of WT-lard group, P < 0.05), reflecting reduced ADAM activity in endothelial cells.
CONCLUSION: FO exerted an antiatherogenic effect on male LDLR(-/-) mice that was accompanied by a reduced release of ADAM17 and ADAM10 substrates from endothelial cells. It is suggested that FO-decreased ADAM activity contributes to improved endothelial barrier function and thus counteracts intimal lipoprotein insudation and macrophage accumulation.
© 2015 American Society for Nutrition.

Entities:  

Keywords:  ADAM; LDLR knockout; atherosclerosis; endothelial permeability; fish oil; shedding

Mesh:

Substances:

Year:  2015        PMID: 25926412     DOI: 10.3945/jn.115.211375

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  10 in total

Review 1.  The Role of ADAM17 in Inflammation-Related Atherosclerosis.

Authors:  Bai-Yi Tang; Jin Ge; Yang Wu; Juan Wen; Xiao-Hong Tang
Journal:  J Cardiovasc Transl Res       Date:  2022-06-01       Impact factor: 4.132

2.  ADAM and ADAMTS disintegrin and metalloproteinases as major factors and molecular targets in vascular malfunction and disease.

Authors:  HaiFeng Yang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2022-01-24

3.  Role of MicroRNA-103a Targeting ADAM10 in Abdominal Aortic Aneurysm.

Authors:  Tong Jiao; Ye Yao; Bo Zhang; Da-Cheng Hao; Qing-Feng Sun; Jing-Bo Li; Chao Yuan; Bao Jing; Yun-Peng Wang; Hai-Yang Wang
Journal:  Biomed Res Int       Date:  2017-03-05       Impact factor: 3.411

4.  Renal ADAM10 and 17: Their Physiological and Medical Meanings.

Authors:  Takashi Kato; Man Hagiyama; Akihiko Ito
Journal:  Front Cell Dev Biol       Date:  2018-11-06

5.  Long non-coding RNA CDKN2B-AS1 reduces inflammatory response and promotes cholesterol efflux in atherosclerosis by inhibiting ADAM10 expression.

Authors:  Haocheng Li; Song Han; Qingfeng Sun; Ye Yao; Shiyong Li; Chao Yuan; Bo Zhang; Bao Jing; Jia Wu; Ye Song; Haiyang Wang
Journal:  Aging (Albany NY)       Date:  2019-03-29       Impact factor: 5.682

6.  Flaxseed (Linum Usitatissimum L.) Supplementation in Patients Undergoing Lipoprotein Apheresis for Severe Hyperlipidemia-A Pilot Study.

Authors:  Dominika Kanikowska; Katarzyna Korybalska; Agnieszka Mickiewicz; Rafał Rutkowski; Agnieszka Kuchta; Maki Sato; Ewelina Kreft; Marcin Fijałkowski; Marcin Gruchała; Maciej Jankowski; Andrzej Bręborowicz; Janusz Witowski
Journal:  Nutrients       Date:  2020-04-18       Impact factor: 5.717

Review 7.  Target Enzymes Considered for the Treatment of Alzheimer's Disease and Parkinson's Disease.

Authors:  Namdoo Kim; Hyuck Jin Lee
Journal:  Biomed Res Int       Date:  2020-11-09       Impact factor: 3.411

8.  Effect of Lentivirus-Mediated miR-499a-3p on Human Umbilical Vein Endothelial Cells.

Authors:  Huilei Zheng; Juan Li; Ying Chen; Danping Gong; Jianlin Wen; Lanxian Mai; Zhiyu Zeng
Journal:  Biomed Res Int       Date:  2020-08-26       Impact factor: 3.411

Review 9.  Junctional Adhesion Molecules: Potential Proteins in Atherosclerosis.

Authors:  Junqi Wang; Xiaoping Chen
Journal:  Front Cardiovasc Med       Date:  2022-07-07

Review 10.  Adipokines, diabetes and atherosclerosis: an inflammatory association.

Authors:  Leandro C Freitas Lima; Valdir de Andrade Braga; Maria do Socorro de França Silva; Josiane de Campos Cruz; Sérgio H Sousa Santos; Matheus M de Oliveira Monteiro; Camille de Moura Balarini
Journal:  Front Physiol       Date:  2015-11-03       Impact factor: 4.566

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.